Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.77 |
| ▸ | TP53 | P04637 | 1/20 | 0.77 |
| ▸ | SLC29A1 | Q99808 | 15/20 | 0.71 |
| ▸ | STAT6 | P42226 | 2/20 | 0.69 |
| ▸ | DPP4 | P27487 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.69 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.69 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.69 |
| ▸ | GAPDH | P04406 | 1/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.69 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.69 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.69 |
| ▸ | PI4KA | P42356 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.69 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.69 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL672036 | 1.00 | SMN1; SMN2 (0.77) | SMN1; SMN2TP53SLC29A1STAT6DPP4 | |
| SCHEMBL7134319 | 1.00 | SMN1; SMN2 (0.77) | SMN1; SMN2TP53SLC29A1STAT6DPP4 | |
| SCHEMBL672035 | 1.00 | SMN1; SMN2 (0.77) | SMN1; SMN2TP53SLC29A1STAT6DPP4 | |
| SCHEMBL30089484 | 1.00 | SMN1; SMN2 (0.77) | SMN1; SMN2TP53SLC29A1STAT6DPP4 | |
| SCHEMBL19488384 | 1.00 | SMN1; SMN2 (0.77) | SMN1; SMN2TP53SLC29A1STAT6DPP4 | |
| SCHEMBL26294910 | 0.91 | SMN1; SMN2 (0.67) | SMN1; SMN2TP53SLC29A1STAT6DPP4 | |
| SCHEMBL8500982 | 0.90 | SLC29A1 (0.78) | SMN1; SMN2SLC29A1STAT6DPP4MEN1 | |
| SCHEMBL2580672 | 0.90 | SMN1; SMN2 (0.72) | SMN1; SMN2TP53SLC29A1STAT6DPP4 | |
| SCHEMBL9350374 | 0.89 | SLC29A1 (0.74) | SMN1; SMN2SLC29A1STAT6DPP4MEN1 | |
| SCHEMBL9347373 | 0.89 | SLC29A1 (0.74) | SMN1; SMN2SLC29A1STAT6DPP4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 312 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | claimed |
| US-20250275946-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2025-09-04 | — | — | US | claimed |
| US-20250076302-A1 | DETECTING THE PRESENCE OF URINARY STONE DISEASE USING A PLURALITY OF URINARY METABOLITES | THE CLEVELAND CLINIC FOUNDATION | 2025-03-06 | — | — | US | claimed |
| US-20240368505-A1 | FLUORINE-FREE CLEANING AGENT, PREPARATION METHOD THEREFOR AND USE THEREOF | Tan Kah Kee Innovation Laboratory (CN) | 2024-11-07 | — | — | US | claimed |
| CN-118879891-A | Method for evaluating PE (polyethylene) based on intestinal flora | 广州市番禺区妇幼保健院(广州市番禺区何贤纪念医院) | 2024-11-01 | — | — | CN | claimed |
| US-20240139325-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2024-05-02 | — | — | US | claimed |
| WO-2023133876-A1 | FLUORINE-FREE CLEANING AGENT, PREPARATION METHOD THEREFOR AND USE THEREOF | 嘉庚创新实验室 | 2023-07-20 | — | — | WO | claimed |
| CN-115943307-A | MR1 ligands and pharmaceutical compositions for immunomodulation | 巴塞尔大学 | 2023-04-07 | — | — | CN | claimed |
| CN-114558061-B | Loquat leaf extract and preparation method and application thereof | 浙江大学 | 2023-04-04 | — | — | CN | claimed |
| US-20230099822-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | UNIVERSITÄT BASEL (CH) | 2023-03-30 | — | — | US | claimed |
| US-7727737-B2 | Kit for rapid determination of thiopurine methyltransferase activity | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2010-06-01 | — | — | US | claimed |
| US-7452689-B2 | Method for rapid determination of thiopurine methyltransferase activity | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2008-11-18 | — | — | US | claimed |
| US-20060263840-A1 | Method for rapid determination of thiopurine methyltransferase activity | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH , A MINNESOTA CORPORATION | 2006-11-23 | — | — | US | claimed |
| US-7105497-B2 | Methods of optimizing drug therapeutic efficacy for treatment of immune-mediated gastrointestinal disorders | Hôpital Sainte-Justine (CA) | 2006-09-12 | — | — | US | claimed |
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | LUMINIDE | 2005-04-14 | — | — | US | claimed |
| WO-2003105862-A1 | IN-VIVO ENERGY DEPLETING STRATEGIES FOR KILLING DRUG-RESISTANT CANCER CELLS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2003-12-24 | — | — | WO | claimed |
| WO-2003076894-A2 | A RAPID IMMUNOCHEMICAL PROCESS FOR MEASURING THIOPURINE METHYLTRANSFERASE REACTION PRODUCTS | BIOLOGIX DIAGNOSTICS, LLC (US) | 2003-09-18 | — | — | WO | claimed |
| US-20030170764-A1 | Rapid, immunochemical process for measuring thiopurine methyltransferase | BIOLOGIX DIAGNOSTICS, LLC | 2003-09-11 | — | — | US | claimed |
| US-5733915-A | CORTICOIDS AND AZATHIOPRINE | GLAXO WELLCOME INC. (US) | 1998-03-31 | — | — | US | claimed |
| EP-0044928-B1 | 1,4;3,6-DIANHYDRO-HEXITE-NITRATE SUBSTITUTED BY PURINE BASES, PROCESS FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL COMPOSITIONS | Dr. Willmar Schwabe GmbH & Co. (DE) | 1985-03-13 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | APEH, PAH, ALAD | SMN1; SMN2 3228/4885TP53 2677/4885SLC29A1 596/4885 |
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | HAVCR2, NR1H4, NR1H3 | SMN1; SMN2 3987/4885TP53 2936/4885SLC29A1 139/4885 |
| US-20230099822-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | MRGPRX1, MRGPRX2, CD47 | SMN1; SMN2 3232/4885TP53 645/4885SLC29A1 650/4885 |
| US-20240139325-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | SLC10A1, HAVCR2, HDGF | SMN1; SMN2 4687/4885TP53 711/4885SLC29A1 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.